Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344914 | 1.00 | ALOX5 (0.41) | ALOX5CYP2C19DAGLAKMT2AMTOR | |
| SCHEMBL10126870 | 0.86 | KMT2A (0.42) | ALOX5CYP2C19KMT2AMTOR | |
| SCHEMBL18045294 | 0.86 | KMT2A (0.42) | ALOX5CYP2C19KMT2AMTOR | |
| SCHEMBL7166960 | 0.85 | ALOX5 (0.42) | ALOX5CYP2C19DAGLAKMT2AMTOR | |
| SCHEMBL27156506 | 0.84 | TP53 (0.41) | KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL1357622 | 0.84 | TP53 (0.41) | KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL16656809 | 0.82 | ALOX5 (0.52) | ALOX5DAGLAMTORPOLBTRPM8 | |
| SCHEMBL6823124 | 0.82 | ALDH1A1 (0.41) | ALOX5KMT2A | |
| SCHEMBL6077517 | 0.82 | ALDH1A1 (0.41) | ALOX5KMT2A | |
| SCHEMBL6077522 | 0.82 | ALDH1A1 (0.41) | ALOX5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2009140447-A1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | ALOX5 3201/4885CYP2C19 3798/4885DAGLA 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.